Dr. Pavol Cekan believes that RNA-based techniques hold the secret to creating reliable, 100% accurate, quantitative and affordable diagnostics for cancer. In the exclusive interview with Elsevier, he describes how this approach could revolutionize cancer treatment, making it possible to precisely determine cancer type and decide on the right medical approach.
“We believe there is so much that can be improved in diagnostics to unlock the full potential of personalized medicine,” says Dr. Cekan. “Every patient deserves a personalized diagnosis that can actually indicate the therapy that they really need. Our MultiplexDX techniques use RNA fluorescence in situ hybridization and RNA sequencing, which have enormous potential for accurate diagnosis.”
While with Professor Tushl’s group, Dr. Cekan developed 8-color RNA FISH techniques, collaborating with Perkin Elmer on their first implementation. This led to the successful simultaneous visualization of 8 RNAs for the first time. It is another major development in the direction of rapid RNA-based diagnostics.
Having seen the success of these techniques, Dr. Cekan began to consider their
broader applications in personalized molecular diagnostics, especially in the
elimination of cancer misdiagnosis. Together with his friend and fellow molecular biologist, Dr. Vladimir Wolf, he founded MultiplexDX, with the mission to create reliable, 100% accurate, quantitative and affordable diagnostics for cancer. He met with Elsevier to discuss how the work at MultiplexDX opens new possibilities in the quest for truly personalized medicine.
You’re welcome to read the full version of Elsevier interview following this link.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.